Skip to main content

Publication: CRC6 post hoc analysis

Publication: CRC6 post hoc analysis
Physical activity and molecular residual disease in stage III colon cancer: findings from Cancer and Leukemia Group B
 
These results found that greater physical activity was associated with improved DFS among patients who were ctDNA-negative. Physical activity and adjuvant celecoxib were associated with favorable survival outcomes regardless of ctDNA status.
 
Zhang GQ, Ma C, Yang VB, Shi Q, Nowak JA, Pederson L, Twombly T, Väyrynen JP, Zhao M, Takashima Y, Shergill A, Kumar P, Couture F, Kuebler JP, Krishnamurthi S, Tan B, O’Reilly EM, Ogino S, Goldberg JE, Brown JC, Jurdi A, Shields AF, Meyerhardt JA. Physical activity and molecular residual disease in stage III colon cancer: findings from Cancer and Leukemia Group B (Alliance)/SWOG 80702 (ONLINE). JNCI: Journal of the National Cancer Institute 2026.
 
Clinicaltrials.gov NCT01150045: other study results are available